Precede Biosciences reposted this
🔬 Exciting progress from our portfolio company, Precede Biosciences! At SABCS 2024, Precede presented their novel ER Transcriptional Dependency Index (PERDI), a blood-based test designed to enhance the use of endocrine therapy in ER+ metastatic #BreastCancer. This innovative approach addresses critical unmet needs in treatment decision-making, with the potential to identify patients who might benefit from monotherapy with emerging oral selective estrogen receptor degraders (SERDs) and antibody-drug conjugates (ADCs). Learn more about Precede’s impactful work here: https://lnkd.in/dNjPqyYK #PartnerNews
